Lisenid
4 employees on LinkedIn · 1 known investors
LisenID develops a molecular diagnostics test and platform that uses Loss of Imprinting (LOI) epigenetic biomarkers combined with AI to detect and predict cancer from routine tumor biopsy samples across multiple cancer types. It targets clinicians and patients facing ambiguous biopsy results, working in the cancer diagnostics field.
Founders & leadership
DN
Dr. Ning ZhouCo-Founder and Chairman
DT
Dr. Tina ChengCo-Founder and CTO
HZ
Hannah ZhouPartner & CEO
Investors · 1
Competitors · 2
by search overlap
Function Health3 shared keywordsFunction Health provides routine whole-body lab testing, advanced imaging, and access to top doctors to help individuals achieve preventive health awareness and disease avoidance. The company combines medical diagnostics with technology to give patients comprehensive health insights.
Cepheid3 shared keywordsCepheid develops molecular diagnostic tests and the GeneXpert System, a scalable platform used by healthcare professionals across settings from core labs to near-patient testing. It also runs a Global Access Program to expand access to diagnostic testing for global public health.
Companies competing with Lisenid for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lisenid do?
- LisenID develops a molecular diagnostics test and platform that uses Loss of Imprinting (LOI) epigenetic biomarkers combined with AI to detect and predict cancer from routine tumor biopsy samples across multiple cancer types. It targets clinicians and patients facing ambiguous biopsy results, working in the cancer diagnostics field.
- Who founded Lisenid?
- Lisenid was founded by Dr. Ning Zhou, Dr. Tina Cheng.
- Who are Lisenid's investors?
- Lisenid's investors include The Innovation Space.